drugset / Trial / NCT04411914
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
Phase 1
Completed
13 enrolled
Temple University
Beth Israel Deaconess Medical Center · collabNational Institute on Drug Abuse (NIDA) · collabUniversity of Pennsylvania · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A dose-escalation study to determine the optimum dose of Clavulanic Acid (CLAV) for effects on craving and efficacy.
Timeline
- Start
- 2020-09-01
- Primary completion
- 2021-11-23
- Completion
- 2022-03-31
Publications
- Background Kim J, John J, Langford D, Walker E, Ward S, Rawls SM. Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice. Amino Acids. 2016 Mar;48(3):689-696. doi: 10.1007/s00726-015-2117-8. Epub 2015 Nov 5.
- Callans LS, Philogene-Khalid H, Jagannathan K, Cunningham R, Yu D, Lu X, Walters MI, Morrison MF. Clavulanic Acid Decreases Cocaine Cue Reactivity in Addiction-Related Brain Areas, a Randomized fMRI Pilot Study. Psychopharmacol Bull. 2024 Apr 4;54(2):8-14. doi: 10.64719/pb.4485.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | clavulanic acid | Small molecule | 1000 mg | — |